Cláudio Galvão de Castro
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Cláudio Galvão de Castro has a total of 221 co-authors. Here are the top co-authors by number of shared publications:
Algemir Lunardi Brunetto
Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul - UFRGS, Porto Alegre, RS, Brazil
8 shared publications- Algemir Lunardi Brunetto
UFRGS, Porto Alegre
7 shared publications - Gilberto Schwartsmann
Department of Internal Medicine, Faculty of Medicine, Federal University of Rio Grande do Sul, Porto Alegre, Brazil
4 shared publications - Lauro J. Gregianin
UFRGS, Porto Alegre
4 shared publications Lauro José Gregianin
Pediatric Oncology Unit, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil
4 shared publications- Adriana Seber
Hospital Samaritano Higienópolis – São Paulo (SP), Brazil
3 shared publications
Latest Publications
- Open Access
- 22 January 2025
- Published by Journal of Bone Marrow Transplantation and Cellular Therapy in JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY
- Vol. 6 (1)
Hematopoietic stem cell transplantation for pediatric acute lymphoblastic leukemia
This article details the 2025 consensus update from the Brazilian Group for Pediatric Bone Marrow Transplantation and the Brazilian Society for Pediatric Oncology regarding hematopoietic stem cell transplantation (HSCT) for pediatric acute lymphoblastic leukemia (ALL). Allogeneic HSCT is the standard treatment for high-risk or relapsed ALL. Key indications include, in first remission, very high risk patients defined by primary induction failure or positive minimal residual disease (MRD) after consolidation. In second remission, it is indicated for early bone marrow relapse, early isolated extramedullary B-cell relapse, and all T-cell ALL relapses. The consensus recommends myeloablative conditioning as standard, preferring total body irradiation based regimens for children over 2–3 years old. The preferred donor hierarchy is a matched sibling, followed by a matched unrelated donor, with bone marrow being the preferred cell source. Post-HSCT monitoring of MRD is critical for guiding interventions and identifying relapse. This document serves as an essential, updated guide for clinical decision-making in this field.
- 22 January 2025
- Published by Journal of Bone Marrow Transplantation and Cellular Therapy in JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY
- Vol. 6 (1)
Open AccessHematopoietic stem cell transplantation for pediatric acute lymphoblastic leukemia
This article details the 2025 consensus update from the Brazilian Group for Pediatric Bone Marrow Transplantation and the Brazilian Society for Pediatric Oncology regarding hematopoietic stem cell transplantation (HSCT) for pediatric acute lymphoblastic leukemia (ALL). Allogeneic HSCT is the standard treatment for high-risk or relapsed ALL. Key indications include, in first remission, very high risk patients defined by primary induction failure or positive minimal residual disease (MRD) after consolidation. In second remission, it is indicated for early bone marrow relapse, early isolated extramedullary B-cell relapse, and all T-cell ALL relapses. The consensus recommends myeloablative conditioning as standard, preferring total body irradiation based regimens for children over 2–3 years old. The preferred donor hierarchy is a matched sibling, followed by a matched unrelated donor, with bone marrow being the preferred cell source. Post-HSCT monitoring of MRD is critical for guiding interventions and identifying relapse. This document serves as an essential, updated guide for clinical decision-making in this field.
- Open Access
- 22 January 2025
- Published by Journal of Bone Marrow Transplantation and Cellular Therapy in JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY
- Vol. 6 (1)
Hematopoietic stem cell transplantation for extracranial germ cell tumors
Malignant extracranial germ cell tumors (GCT) are uncommon in the pediatric population. Most affected children can achieve cure using conventional chemotherapy combined with appropriate local control. The role of high-dose chemotherapy with autologous stem cell transplantation (HDCT/ASCT) in GCT has been studied mainly in adult cohorts. In this article, we reviewed the current evidence and indications for HDCT/ASCT in the management of pediatric GCT.
- 22 January 2025
- Published by Journal of Bone Marrow Transplantation and Cellular Therapy in JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY
- Vol. 6 (1)
Open AccessHematopoietic stem cell transplantation for extracranial germ cell tumors
Malignant extracranial germ cell tumors (GCT) are uncommon in the pediatric population. Most affected children can achieve cure using conventional chemotherapy combined with appropriate local control. The role of high-dose chemotherapy with autologous stem cell transplantation (HDCT/ASCT) in GCT has been studied mainly in adult cohorts. In this article, we reviewed the current evidence and indications for HDCT/ASCT in the management of pediatric GCT.
- Open Access
- 22 January 2025
- Published by Journal of Bone Marrow Transplantation and Cellular Therapy in JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY
- Vol. 6 (1)
Central nervous system tumors
Central nervous system (CNS) tumors represent one of the most prevalent groups of neoplasms in the pediatric population. Recent advances in molecular biology and neuro-oncology have led to continuous updates in the classification of these tumors, which poses significant diagnostic challenges, particularly in low- and middle-income countries, with limited access to advanced diagnostic tools. The therapeutic approach varies according to tumor subtype, often requiring complex and resource-intensive protocols. One such strategy involves the use of high-dose chemotherapy followed by autologous stem cell rescue, which has shown promise in improving outcomes for select pediatric patients with CNS tumors. However, implementation of this therapy in countries like Brazil faces logistical, financial, and clinical practice challenges. This article aimed to provide a brief overview and suggestions to use high-dose chemotherapy with autologous stem cell transplantation in the treatment of pediatric CNS tumors. We discussed practical considerations for patient selection, and conditioning regimens. Our objectives were to optimize and guide current practices by proposing strategies that maybe feasible in the Brazilian public and private healthcare systems.
- 22 January 2025
- Published by Journal of Bone Marrow Transplantation and Cellular Therapy in JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY
- Vol. 6 (1)
Open AccessCentral nervous system tumors
Central nervous system (CNS) tumors represent one of the most prevalent groups of neoplasms in the pediatric population. Recent advances in molecular biology and neuro-oncology have led to continuous updates in the classification of these tumors, which poses significant diagnostic challenges, particularly in low- and middle-income countries, with limited access to advanced diagnostic tools. The therapeutic approach varies according to tumor subtype, often requiring complex and resource-intensive protocols. One such strategy involves the use of high-dose chemotherapy followed by autologous stem cell rescue, which has shown promise in improving outcomes for select pediatric patients with CNS tumors. However, implementation of this therapy in countries like Brazil faces logistical, financial, and clinical practice challenges. This article aimed to provide a brief overview and suggestions to use high-dose chemotherapy with autologous stem cell transplantation in the treatment of pediatric CNS tumors. We discussed practical considerations for patient selection, and conditioning regimens. Our objectives were to optimize and guide current practices by proposing strategies that maybe feasible in the Brazilian public and private healthcare systems.
- 1 July 2020
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 61 (10) , 2536-2537
Continuous high-dose ivermectin appears to be safe in patients with acute myelogenous leukemia and could inform clinical repurposing for COVID-19 infection
(2020). Continuous high-dose ivermectin appears to be safe in patients with acute myelogenous leukemia and could inform clinical repurposing for COVID-19 infection. Leukemia & Lymphoma. Ahead of Print.
- 1 July 2020
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 61 (10) , 2536-2537
Continuous high-dose ivermectin appears to be safe in patients with acute myelogenous leukemia and could inform clinical repurposing for COVID-19 infection
(2020). Continuous high-dose ivermectin appears to be safe in patients with acute myelogenous leukemia and could inform clinical repurposing for COVID-19 infection. Leukemia & Lymphoma. Ahead of Print.
- Open Access
- 20 April 2020
- Published by Elsevier in Jornal de Pediatria
- Vol. 97 (2) , 204-210
Epidemiological evaluation and survival of children with acute myeloid leukemia
- 20 April 2020
- Published by Elsevier in Jornal de Pediatria
- Vol. 97 (2) , 204-210
Open AccessEpidemiological evaluation and survival of children with acute myeloid leukemia
- Open Access
- 13 March 2020
- Published by Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein in Einstein (São Paulo)
- Vol. 18, eAE4799
Brazilian Nutritional Consensus in Hematopoietic Stem Cell Transplantation: Graft- versus -host disease
The Brazilian Consensus on Nutrition in Hematopoietic Stem Cell Transplantation: Graft- versus -host disease was approved by Sociedade Brasileira de Transplante de Medula Óssea , with the participation of 26 Brazilian hematopoietic stem cell transplantation centers. It describes the main nutritional protocols in cases of Graft- versus -host disease, the main complication of hematopoietic stem cell transplantation.
- 13 March 2020
- Published by Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein in Einstein (São Paulo)
- Vol. 18, eAE4799
Open AccessBrazilian Nutritional Consensus in Hematopoietic Stem Cell Transplantation: Graft- versus -host disease
The Brazilian Consensus on Nutrition in Hematopoietic Stem Cell Transplantation: Graft- versus -host disease was approved by Sociedade Brasileira de Transplante de Medula Óssea , with the participation of 26 Brazilian hematopoietic stem cell transplantation centers. It describes the main nutritional protocols in cases of Graft- versus -host disease, the main complication of hematopoietic stem cell transplantation.
- Open Access
- 23 January 2017
- Published by Elsevier in Revista Brasileira de Ginecologia e Obstetrícia
- Vol. 39 (1) , 1-3
Paradoxes of hematology: When the old disappears and the new does not arrive
- 23 January 2017
- Published by Elsevier in Revista Brasileira de Ginecologia e Obstetrícia
- Vol. 39 (1) , 1-3
Open AccessParadoxes of hematology: When the old disappears and the new does not arrive
- 29 September 2014
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 50 (1) , 145
Fecal microbiota transplant after hematopoietic SCT: report of a successful case
- 29 September 2014
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 50 (1) , 145
Fecal microbiota transplant after hematopoietic SCT: report of a successful case
- Open Access
- 1 June 2014
- Published by Elsevier in Clinical Microbiology and Infection
- Vol. 20 (6) , 580-585
Improvement in the outcome of invasive fusariosis in the last decade
- 1 June 2014
- Published by Elsevier in Clinical Microbiology and Infection
- Vol. 20 (6) , 580-585
Open AccessImprovement in the outcome of invasive fusariosis in the last decade
- Open Access
- 1 May 2014
- Published by Oxford University Press (OUP) in Pain Medicine
- Vol. 15 (5) , 807-819
Degree of Knowledge of Health Care Professionals About Pain Management and Use of Opioids in Pediatrics
Objective. To evaluate the degree of knowledge about pain management and opioids use by professionals working at three pediatric units.Design. This is
- 1 May 2014
- Published by Oxford University Press (OUP) in Pain Medicine
- Vol. 15 (5) , 807-819
Open AccessDegree of Knowledge of Health Care Professionals About Pain Management and Use of Opioids in Pediatrics
Objective. To evaluate the degree of knowledge about pain management and opioids use by professionals working at three pediatric units.Design. This is